BIIB34:BVMF
Biogen
230,10 BRL
0,00%
(0,00) 1D
4-ноя., 15:38:07 GMT-3 · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
37,46 млд
Avg. vol.
9,00
Volume
0,00
52-wk high
230,10 BRL
52-wk low
145,65 BRL
Shares outstanding
147,82 млн
No. of employees
8 миң
Mkt. cap
37,46 млд
Avg. vol.
9,00
Volume
0,00
52-wk high
230,10 BRL
52-wk low
145,65 BRL
Shares outstanding
147,82 млн
No. of employees
8 миң
News stories
From web sources and news partners
Yahoo! Finance Canada
·
28 мүнөт мурун
ANGX,CDNL,NTHI,AMRC,PRTS,AGMB,LIEN,RGCO,ATLO,SELF,TISI,AN,AIAI,EQPT,REFI,MTDR,BRID,AFCG,SRTS,BGDE,WVVI,PHIO,PAM,GME | Stock Prices | Quote Comparison - Yahoo Finance
The Motley Fool
·
2 саат мурун
History Says Every S&P 500 Bear Market Has Ended the Same Way. Here's the Pattern.
FourWeekMBA
·
45 мүнөт мурун
Nvidia’s CEO-Exit Drop Took $384 Off a $100K S&P 500 Fund
Bloomberg.com
·
23 саат мурун
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen
CEOChris Viehbacher
Employees7,5 миң
Founded1978
HeadquartersКембридж, Массачусетс, Америка Кошмо Штаттары
SectorHealth Care
Industry-
Websitebiogen.com